201 related articles for article (PubMed ID: 29350455)
1. A novel prognostic six-CpG signature in glioblastomas.
Yin AA; Lu N; Etcheverry A; Aubry M; Barnholtz-Sloan J; Zhang LH; Mosser J; Zhang W; Zhang X; Liu YH; He YL
CNS Neurosci Ther; 2018 Mar; 24(3):167-177. PubMed ID: 29350455
[TBL] [Abstract][Full Text] [Related]
2. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
3. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.
Kang EM; Yin AA; He YL; Chen WJ; Etcheverry A; Aubry M; Barnholtz-Sloan J; Mosser J; Zhang W; Zhang X
CNS Neurosci Ther; 2019 Sep; 25(9):937-950. PubMed ID: 31016891
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.
Yin A; Shang Z; Etcheverry A; He Y; Aubry M; Lu N; Liu Y; Mosser J; Lin W; Zhang X; Dong Y
Oncoimmunology; 2021 Mar; 10(1):1902071. PubMed ID: 33854822
[TBL] [Abstract][Full Text] [Related]
5. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
7. Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Wang J; Zhang M; Liu YF; Yao Y; Ji YS; Etcheverry A; Chen K; Song BQ; Lin W; Yin A; He YL
Epigenomics; 2022 Oct; 14(20):1233-1247. PubMed ID: 36444681
[TBL] [Abstract][Full Text] [Related]
8. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
9. RNA sequencing and Immunohistochemistry Reveal
Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
11. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
[TBL] [Abstract][Full Text] [Related]
12. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
Brigliadori G; Foca F; Dall'Agata M; Rengucci C; Melegari E; Cerasoli S; Amadori D; Calistri D; Faedi M
J Neurooncol; 2016 Jun; 128(2):333-9. PubMed ID: 27029617
[TBL] [Abstract][Full Text] [Related]
13. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
[TBL] [Abstract][Full Text] [Related]
14. A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
Li B; Wang J; Liu F; Li R; Hu W; Etcheverry A; Aubry M; Mosser J; Yin A; Zhang X; Wu Y; Chen K; He Y; Wang L
J Oncol; 2022; 2022():6345160. PubMed ID: 35712126
[TBL] [Abstract][Full Text] [Related]
15. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
17. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
18. An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature.
Chiang JH; Cheng WS; Hood L; Tian Q
OMICS; 2014 May; 18(5):310-23. PubMed ID: 24601786
[TBL] [Abstract][Full Text] [Related]
19. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Xiu J; Piccioni D; Juarez T; Pingle SC; Hu J; Rudnick J; Fink K; Spetzler DB; Maney T; Ghazalpour A; Bender R; Gatalica Z; Reddy S; Sanai N; Idbaih A; Glantz M; Kesari S
Oncotarget; 2016 Apr; 7(16):21556-69. PubMed ID: 26933808
[TBL] [Abstract][Full Text] [Related]
20. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
